SCHEMBL31209579

SCHEMBL31209579

CC(C)(C)OC(=O)N1CC[C@@H](N2CC3(CCC3)C2)C1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.46
▸ EPHX1 P07099 1/20 0.44
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ RECQL P46063 1/20 0.41
▸ PREP P48147 1/20 0.39
▸ USP30 Q70CQ3 2/20 0.39
▸ HCAR1 Q9BXC0 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ GPR119 Q8TDV5 1/20 0.39
▸ JAK2 O60674 1/20 0.38
▸ JAK1 P23458 1/20 0.38
▸ PDE4B Q07343 1/20 0.38
▸ EGFR P00533 1/20 0.38
▸ SRC P12931 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31209885 1.00 HPGD (0.46) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL31015125 0.85 MEN1 (0.45) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL31209170 0.84 HPGD (0.42) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL4264465 0.84 HPGD (0.55) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL13085760 0.84 HPGD (0.55) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL31209057 0.84 HPGD (0.51) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL14196264 0.84 HPGD (0.51) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL34473834 0.84 HPGD (0.51) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL34474698 0.83 HPGD (0.43) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL1094778 0.82 HPGD (0.57) HPGDEPHX1MEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368193-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2024-11-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368193-A1 KRAS INHIBITORS KRAS, NRAS, HRAS HPGD 2249/4885EPHX1 2715/4885MEN1 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback